Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024

世界の女性健康管理市場:薬物別(プロリア、デノスマブ、エビスタ、ミレーナ、ゾメタ、リクラスト、ヌバリング、プレマリン、アクトン)、用途別(女性不妊、閉経後骨粗鬆症、子宮内膜症、避妊、PCOS、閉経)

◆タイトル:Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024
◆商品コード:PH 7507
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年1月30日
◆ページ数:147
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥593,250見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は、女性健康管理の世界市場規模が2019年96億ドルから2024年178憶ドルまで年平均13.2%成長すると予測しています。本調査レポートでは、世界の女性健康管理市場を広く調査・分析し、市場概要、用途別(閉経後骨粗鬆症、避妊薬、閉経期、ホルモン不妊症、多嚢胞性卵巣症候群、子宮内膜症、その他の用途)分析、地域別分析、競合動向、企業概要などで取りまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の女性健康管理市場:用途別(閉経後骨粗鬆症、避妊薬、閉経期、ホルモン不妊症、多嚢胞性卵巣症候群、子宮内膜症、その他の用途)
・世界の女性健康管理市場:地域別
・競合動向
・企業概要

“Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.”
The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth.

“Prolia is the largest and fastest-growing segment of the market.”
On the basis of drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. The increasing unit demand for prolia due to the high prevalence of postmenopausal osteoporosis among women in the US is one of the major factors responsible for the large share and high growth rate of this drug.

“The postmenopausal osteoporosis segment accounted for the largest share in 2019.”
Based on application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market in 2018. The growing prevalence of postmenopausal osteoporosis and the focus of pharmaceutical players on providing effective drugs for the treatment of postmenopausal osteoporosis are some of the key factors supporting the growth of this segment. This segment is also expected to register the highest CAGR during the forecast period.

“North America to be the largest and the fastest-growing regional market.”
North America, which comprises the US and Canada, forms the largest market for women’s healthcare. Growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending are some of the major factors responsible for the large share and high growth of this market. Additionally, the increasing median age of first-time pregnancies and the growing prevalence of PCOS & postmenopausal osteoporosis also propels the market growth in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
• By Designation: C-level (33%), D-level (29%), and Others (38%)
• By Region: North America (58%), Europe (19%), Asia (14%), and the RoW (9%)

List of Companies Profiled in the Report
• Bayer AG (Germany)
• Allergan (Dublin)
• Merck & Co. (US)
• Pfizer Inc. (US)
• Amgen (US)
• Agile Therapeutics Inc. (US)
• Ferring Pharmaceuticals (US)
• Mylan N.V. (US)
• Lupin (India)
• Blairex Laboratories (US)
• Apothecus Pharmaceutical (US)
• Eli Lilly And Company (US)
• Novartis AG (Switzerland)
• Johnson & Johnson (US)

Research Coverage:
This report provides a study of the women’s healthcare market. It aims at estimating the size and future growth potential of the market across different segments, such as drug, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall women’s healthcare market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to position their business better and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

【レポートの目次】

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 20)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimations
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 28)
4 Premium Insights (Page No. – 31)
4.1 Women’s Healthcare Market Overview
4.2 Market, By Drug (2019–2024)
4.3 Market, By Application (2019 vs 2024)
4.4 Market: Geographic Growth Opportunities
5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Incidence of Chronic Health Conditions Among Women
5.2.1.2 Demand for Contraceptives to Prevent Unintended Pregnancies
5.2.1.3 Government Initiatives to Curb Population Growth
5.2.1.4 Growing Focus on Product R&D
5.2.2 Market Opportunities
5.2.2.1 Emerging Markets
5.2.3 Market Challenges
5.2.3.1 Reluctance to Use Contraceptives
5.2.3.2 Market, By Drug
5.3 Introduction
5.4 Prolia
5.4.1 Prolia Accounts for the Largest Share of the Market
5.5 Xgeva
5.5.1 Xgeva is Primarily Marketed in the US and European Countries
5.6 Forteo
5.6.1 Eli Lilly is Expected to Experience A Revenue Decline in the Coming Years Due to the Patent Expiry of Forteo
5.7 Mirena
5.7.1 Mirena is Widely Accepted Amongst End Users Owing to the Minimal Side-Effects Associated With It
5.8 Nuvaring
5.8.1 Nuvaring is One of the Top-Selling Drugs From Merck (US) in the Women’s Health Category
5.9 Premarin
5.9.1 Premarin is Used for the Treatment of Osteoporosis in Women
5.10 Ortho Tri-Cy Lo (28)
5.10.1 Growing Number of Anda to Market Generic Versions of Ortho Tri-Cy Lo (28) to Hamper Its Sales in the Coming Years
5.11 Evista
5.11.1 Intense Generic Competition has Led to A Year-On-Year Decline in Evista’s Sales
5.12 Reclast/Aclasta
5.12.1 Aclasta has More Benefits as Compared to Other Drugs
5.13 Zometa
5.13.1 Early Patent Expiry of Zometa in the US and Europe has Affected Its Sales
5.14 Minastrin 24 FE
5.14.1 Availability of Low-Priced Generic Versions of Minastrin 24 FE is One of the Main Reasons for the Lower Sales of This Drug
5.15 Actonel
5.15.1 Intense Competition in the Osteoporosis Market has Led to A Sales Decline in Actonel in the Last Few Years
5.16 Pipeline Drugs
6 Women’s Healthcare Market, By Application (Page No. – 65)
6.1 Introduction
6.2 Postmenopausal Osteoporosis
6.2.1 High Prevalence of Osteoporosis in Women has Prompted Companies to Focus on This Therapeutic Area
6.3 Contraceptives
6.3.1 Benefits Offered By Contraceptives Driving Their Demand Among End Users
6.4 Menopause
6.4.1 Demand for Non-Hormonal Therapies has Increased Over the Last Few Years
6.5 Hormonal Infertility
6.5.1 Increasing Awareness About Ovulation Health to Support Market Growth
6.6 Polycystic Ovary Syndrome
6.6.1 Growing Prevalence of Pcos is Responsible for the Market Growth
6.7 Endometriosis
6.7.1 Orilissa is the First and Only Oral Treatment Specifically Available for Women With Endometriosis Pain
6.8 Other Applications
7 Women’s Healthcare Market, By Region (Page No. – 79)
7.1 Introduction
7.2 North America
7.2.1 US
7.2.1.1 Strong Economy and High Contraception Awareness are Key Factors Driving Market Growth in the US
7.2.2 Canada
7.2.2.1 Growing Prevalence of Pcos and Obesity to Support the Market Growth in Canada
7.3 Europe
7.3.1 Germany
7.3.1.1 Germany Holds the Largest Share of the Market in Europe
7.3.2 UK
7.3.2.1 Government Support and Favorable Training Programs are Major Market Drivers in the UK
7.3.3 France
7.3.3.1 High Prevalence of Lifestyle Disorders Among Women in France to Support the Market Growth
7.3.4 Spain
7.3.4.1 Improved Healthcare Expenditure to Support the Market in Spain
7.3.5 Italy
7.3.5.1 Relatively High Awareness of Contraceptives to Drive Market Growth in Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.1.1 Japan Dominates the APAC Market for Women’s Healthcare
7.4.2 China
7.4.2.1 Growing Population and Urbanization are Factors Responsible for the Growth of the Market in China
7.4.3 India
7.4.3.1 Increasing Government Initiatives to Curb Population Growth Will Drive Market Growth in India
7.4.4 Rest of APAC
7.5 Latin America
7.5.1 Increasing Lifestyle Diseases and Awareness Among Women to Drive Market Growth in Latin America
7.6 Middle East & Africa
7.6.1 Increasing Government Initiatives to Curb Population Growth Will Drive Market Growth in India
8 Competitive Landscape (Page No. – 110)
8.1 Overview
8.2 Market Share Analysis
8.3 Competitive Leadership Mapping
8.3.1 Visionary Leaders
8.3.2 Dynamic Differentiators
8.3.3 Innovators
8.3.4 Emerging Players
9 Company Profiles (Page No. – 114)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
9.1 Bayer AG
9.2 Allergan
9.3 Merck & Co
9.4 Pfizer
9.5 Amgen
9.6 Agile Therapeutics
9.7 Ferring Pharmaceuticals
9.8 Mylan NV
9.9 Lupin Limited
9.10 Blairex Laboratories, Inc.
9.11 Apothecus Pharmaceutical Corporation
9.12 Eli Lilly and Company
9.13 Novartis AG
9.14 Johnson & Johnson Services Inc.
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
10 Appendix (Page No. – 140)
10.1 Discussion Guide
10.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
10.3 Available Customizations
10.4 Related Reports
10.5 Author Details

List of Tables (127 Tables)
Table 1 Women’s Healthcare Market, By Drug, 2017–2024 (USD Million)
Table 2 Prolia: Product Highlights
Table 3 Market for Prolia, By Region, 2017–2024 (USD Million)
Table 4 North America: Market for Prolia, By Country, 2017–2024 (USD Million)
Table 5 Europe: Market for Prolia, By Country, 2017–2024 (USD Million)
Table 6 APAC: Market for Prolia, By Country, 2017–2024 (USD Million)
Table 7 Xgeva: Product Highlights
Table 8 Market for Xgeva, By Region, 2017–2024 (USD Million)
Table 9 North America: Market for Xgeva, By Country, 2017–2024 (USD Million)
Table 10 Europe: Market for Xgeva, By Country, 2017–2024 (USD Million)
Table 11 APAC: Women’s Healthcare Market for Xgeva, By Country, 2017–2024 (USD Million)
Table 12 Forteo: Product Highlights
Table 13 Market for Forteo, By Region, 2017–2024 (USD Million)
Table 14 North America: Market for Forteo, By Country, 2017–2024 (USD Million)
Table 15 Europe: Market for Forteo, By Country, 2017–2024 (USD Million)
Table 16 APAC: Market for Forteo, By Country, 2017–2024 (USD Million)
Table 17 Mirena: Product Highlights
Table 18 Market for Mirena, By Region, 2017–2024 (USD Million)
Table 19 North America: Market for Mirena, By Country, 2017–2024 (USD Million)
Table 20 Europe: Market for Mirena, By Country, 2017–2024 (USD Million)
Table 21 APAC: Market for Mirena, By Country, 2017–2024 (USD Million)
Table 22 Nuvaring: Product Highlights
Table 23 Market for Nuvaring, By Region, 2017–2024 (USD Million)
Table 24 North America: Market for Nuvaring, By Country, 2017–2024 (USD Million)
Table 25 Europe: Market for Nuvaring, By Country, 2017–2024 (USD Million)
Table 26 APAC: Market for Nuvaring, By Country, 2017–2024 (USD Million)
Table 27 Premarin: Product Highlights
Table 28 Market for Premarin, By Region, 2017–2024 (USD Million)
Table 29 North America: Market for Premarin, By Country, 2017–2024 (USD Million)
Table 30 Europe: Market for Premarin, By Country, 2017–2024 (USD Million)
Table 31 APAC: Market for Premarin, By Country, 2017–2024 (USD Million)
Table 32 Ortho Tri-Cy Lo (28): Product Highlights
Table 33 Market for Ortho Tri-Cy Lo (28), By Region, 2017–2024 (USD Million)
Table 34 North America: Market for Ortho Tri-Cy Lo (28), By Country, 2017–2024 (USD Million)
Table 35 Europe: Market for Ortho Tri-Cy Lo (28), By Country, 2017–2024 (USD Million)
Table 36 APAC: Market for Ortho Tri-Cy Lo (28), By Country, 2017–2024 (USD Million)
Table 37 Evista: Product Highlights
Table 38 Market for Evista, By Region, 2017–2024 (USD Million)
Table 39 North America: Market for Evista, By Country, 2017–2024 (USD Million)
Table 40 Europe: Women’s Healthcare Market for Evista, By Country, 2017–2024 (USD Million)
Table 41 APAC: Market for Evista, By Country, 2017–2024 (USD Million)
Table 42 Reclast/Aclasta: Product Highlights
Table 43 Market for Reclast/Aclasta, By Region, 2017–2024 (USD Million)
Table 44 North America: Market for Reclast/Aclasta, By Country, 2017–2024 (USD Million)
Table 45 Europe: Market for Reclast/Aclasta, By Country, 2017–2024 (USD Million)
Table 46 APAC: Market for Reclast/Aclasta, By Country, 2017–2024 (USD Million)
Table 47 Zometa: Product Highlights
Table 48 Women’s Healthcare Market for Zometa, By Region, 2017–2024 (USD Million)
Table 49 North America: Market for Zometa, By Country, 2017–2024 (USD Million)
Table 50 Europe: Market for Zometa, By Country, 2017–2024 (USD Million)
Table 51 APAC: Market for Zometa, By Country, 2017–2024 (USD Million)
Table 52 Minastrin 24 FE: Product Highlights
Table 53 North America: Market for Minastrin 24 FE, By Country, 2017–2024 (USD Million)
Table 54 Actonel: Product Highlights
Table 55 Market for Actonel, By Region, 2017–2024 (USD Million)
Table 56 North America: Market for Actonel, By Country, 2017–2024 (USD Million)
Table 57 Europe: Market for Actonel, By Country, 2017–2024 (USD Million)
Table 58 APAC: Market for Actonel, By Country, 2017–2024 (USD Million)
Table 59 Indicative List of Drugs in Phase III
Table 60 Market, By Application, 2017–2024 (USD Million)
Table 61 Market for Postmenopausal Osteoporosis, By Region, 2017–2024 (USD Million)
Table 62 North America: Women’s Healthcare Market for Postmenopausal Osteoporosis, By Country, 2017–2024 (USD Million)
Table 63 Europe: Market for Postmenopausal Osteoporosis, By Country, 2017–2024 (USD Million)
Table 64 APAC: Market for Postmenopausal Osteoporosis, By Country, 2017–2024 (USD Million)
Table 65 Market for Contraception, By Region, 2017–2024 (USD Million)
Table 66 North America: Market for Contraception, By Country, 2017–2024 (USD Million)
Table 67 Europe: Market for Contraception, By Country, 2017–2024 (USD Million)
Table 68 APAC: Market for Contraception, By Country, 2017–2024 (USD Million)
Table 69 Market for Menopause, By Region, 2017–2024 (USD Million)
Table 70 North America: Women’s Healthcare Market for Menopause, By Country, 2017–2024 (USD Million)
Table 71 Europe: Market for Menopause, By Country, 2017–2024 (USD Million)
Table 72 APAC: Market for Menopause, By Country, 2017–2024 (USD Million)
Table 73 Market for Hormonal Infertility, By Region, 2017–2024 (USD Million)
Table 74 North America: Market for Hormonal Infertility, By Country, 2017–2024 (USD Million)
Table 75 Europe: Market for Hormonal Infertility, By Country, 2017–2024 (USD Million)
Table 76 APAC: Market for Hormonal Infertility, By Country, 2017–2024 (USD Million)
Table 77 Market for Polycystic Ovary Syndrome, By Region, 2017–2024 (USD Million)
Table 78 North America: Women’s Healthcare Market for Polycystic Ovary Syndrome, By Country, 2017–2024 (USD Million)
Table 79 Europe: Market for Polycystic Ovary Syndrome, By Country, 2017–2024 (USD Thousand)
Table 80 APAC: Market for Polycystic Ovary Syndrome, By Country, 2017–2024 (USD Million)
Table 81 Market for Endometriosis, By Region, 2017–2024 (USD Million)
Table 82 North America: Market for Endometriosis, By Country, 2017–2024 (USD Million)
Table 83 Europe: Market for Endometriosis, By Country, 2017–2024 (USD Thousand)
Table 84 APAC: Market for Endometriosis, By Country, 2017–2024 (USD Million)
Table 85 Market for Other Applications, By Region, 2017–2024 (USD Million)
Table 86 North America: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 87 Europe: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 88 APAC: Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 89 Market, By Region, 2017–2024 (USD Million)
Table 90 North America: Market, By Country, 2017–2024 (USD Million)
Table 91 North America: Women’s Healthcare Market, By Drug, 2017–2024 (USD Million)
Table 92 North America: Market, By Application, 2017–2024 (USD Million)
Table 93 US: Market, By Drug, 2017–2024 (USD Million)
Table 94 US: Market, By Application, 2017–2024 (USD Million)
Table 95 Canada: Market, By Drug, 2017–2024 (USD Million)
Table 96 Canada: Market, By Application, 2017–2024 (USD Million)
Table 97 Europe: Market, By Country, 2017–2024 (USD Million)
Table 98 Europe: Market, By Drug, 2017–2024 (USD Million)
Table 99 Europe: Market, By Application, 2017–2024 (USD Million)
Table 100 Germany: Market, By Drug, 2017–2024 (USD Million)
Table 101 Germany: Market, By Application, 2017–2024 (USD Million)
Table 102 UK: Women’s Healthcare Market, By Drug, 2017–2024 (USD Million)
Table 103 UK: Market, By Application, 2017–2024 (USD Million)
Table 104 France: Market, By Drug, 2017–2024 (USD Million)
Table 105 France: Market, By Application, 2017–2024 (USD Million)
Table 106 Spain: Market, By Drug, 2017–2024 (USD Million)
Table 107 Spain: Market, By Application, 2017–2024 (USD Thousand)
Table 108 Italy: Market, By Drug, 2017–2024 (USD Million)
Table 109 Italy: Market, By Application, 2017–2024 (USD Million)
Table 110 RoE: Market, By Drug, 2017–2024 (USD Million)
Table 111 RoE: Market, By Application, 2017–2024 (USD Million)
Table 112 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 113 Asia Pacific: Market, By Drug, 2017–2024 (USD Million)
Table 114 Asia Pacific: Market, By Application, 2017–2024 (USD Million)
Table 115 Japan: Indicative List of Conferences
Table 116 Japan: Women’s Healthcare Market, By Drug, 2017–2024 (USD Million)
Table 117 Japan: Market, By Application, 2017–2024 (USD Million)
Table 118 China: Market, By Drug, 2017–2024 (USD Million)
Table 119 China: Market, By Application, 2017–2024 (USD Million)
Table 120 India: Market, By Drug, 2017–2024 (USD Million)
Table 121 India: Market, By Application, 2017–2024 (USD Million)
Table 122 RoAPAC: Market, By Drug, 2017–2024 (USD Million)
Table 123 RoAPAC: Women’s Healthcare Market, By Application, 2017–2024 (USD Million)
Table 124 Latin America: Market, By Drug, 2017–2024 (USD Million)
Table 125 Latin America: Market, By Application, 2017–2024 (USD Million)
Table 126 Middle East & Africa: Market, By Drug, 2017–2024 (USD Million)
Table 127 Middle East & Africa: Market, By Application, 2017–2024 (USD Million)

List of Figures (27 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Women’s Healthcare Market, By Drug, 2019 vs 2024 (USD Million)
Figure 7 Market, By Application, 2019 vs 2024 (USD Million)
Figure 8 Geographical Snapshot of the Market
Figure 9 Growing Incidence of Chronic Health Conditions Among Women is A Major Factor Driving the Market
Figure 10 Prolia to Witness the Highest Growth During the Forecast Period
Figure 11 Postmenopausal Osteoporosis to Dominate the Women’s Healthcare Applications Market During the Forecast Period
Figure 12 Asia Pacific is the Fastest-Growing Regional Market for Women’s Healthcare Market
Figure 13 Market: Drivers, Opportunities, and Challenges
Figure 14 North America: Market Snapshot
Figure 15 Europe: Market Snapshot
Figure 16 Women’s Healthcare Market Share Analysis, By Key Player, 2018
Figure 17 Competitive Leadership Mapping of the Women’s Healthcare Market Market– Overall Market, 2018
Figure 18 Bayer AG: Company Snapshot
Figure 19 Allergan: Company Snapshot
Figure 20 Merck & Co: Company Snapshot
Figure 21 Pfizer: Company Snapshot
Figure 22 Amgen: Company Snapshot
Figure 23 Mylan NV: Company Snapshot
Figure 24 Lupin Limited: Company Snapshot
Figure 25 Eli Lilly and Company: Company Snapshot
Figure 26 Novartis AG: Company Snapshot
Figure 27 Johnson & Johnson Services, Inc. : Company Snapshot

★調査レポート[世界の女性健康管理市場:薬物別(プロリア、デノスマブ、エビスタ、ミレーナ、ゾメタ、リクラスト、ヌバリング、プレマリン、アクトン)、用途別(女性不妊、閉経後骨粗鬆症、子宮内膜症、避妊、PCOS、閉経)] ( Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024 / PH 7507) 販売に関する免責事項
[世界の女性健康管理市場:薬物別(プロリア、デノスマブ、エビスタ、ミレーナ、ゾメタ、リクラスト、ヌバリング、プレマリン、アクトン)、用途別(女性不妊、閉経後骨粗鬆症、子宮内膜症、避妊、PCOS、閉経)] ( Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024 / PH 7507) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆